Učitavanje...

Is It the Twilight of BACE1 Inhibitors?

β-secretase (BACE1) has been regarded as a prime target for the development of amyloid beta (Aβ) lowering drugs in the therapy of Alzheimer´s disease (AD). Although the enzyme was discovered in 1991 and helped to formulate the Aβ hypothesis as one of the very important features of AD etiopathogenesi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Curr Neuropharmacol
Glavni autori: Hrabinova, Martina, Pejchal, Jaroslav, Kucera, Tomas, Jun, Daniel, Schmidt, Monika, Soukup, Ondrej
Format: Artigo
Jezik:Inglês
Izdano: Bentham Science Publishers 2021
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903497/
https://ncbi.nlm.nih.gov/pubmed/32359337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X18666200503023323
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!